Cargando…
Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
SIMPLE SUMMARY: Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296639/ https://www.ncbi.nlm.nih.gov/pubmed/37370776 http://dx.doi.org/10.3390/cancers15123166 |
_version_ | 1785063697142513664 |
---|---|
author | Lawson, Alexander Kamarajah, Sivesh K. Parente, Alessandro Pufal, Kamil Sundareyan, Ramanivas Pawlik, Timothy M. Ma, Yuk Ting Shah, Tahir Kharkhanis, Salil Dasari, Bobby V. M. |
author_facet | Lawson, Alexander Kamarajah, Sivesh K. Parente, Alessandro Pufal, Kamil Sundareyan, Ramanivas Pawlik, Timothy M. Ma, Yuk Ting Shah, Tahir Kharkhanis, Salil Dasari, Bobby V. M. |
author_sort | Lawson, Alexander |
collection | PubMed |
description | SIMPLE SUMMARY: Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. ABSTRACT: Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. |
format | Online Article Text |
id | pubmed-10296639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102966392023-06-28 Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Lawson, Alexander Kamarajah, Sivesh K. Parente, Alessandro Pufal, Kamil Sundareyan, Ramanivas Pawlik, Timothy M. Ma, Yuk Ting Shah, Tahir Kharkhanis, Salil Dasari, Bobby V. M. Cancers (Basel) Systematic Review SIMPLE SUMMARY: Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. ABSTRACT: Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. MDPI 2023-06-13 /pmc/articles/PMC10296639/ /pubmed/37370776 http://dx.doi.org/10.3390/cancers15123166 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Lawson, Alexander Kamarajah, Sivesh K. Parente, Alessandro Pufal, Kamil Sundareyan, Ramanivas Pawlik, Timothy M. Ma, Yuk Ting Shah, Tahir Kharkhanis, Salil Dasari, Bobby V. M. Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
title | Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
title_full | Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
title_fullStr | Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
title_short | Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
title_sort | outcomes of transarterial embolisation (tae) vs. transarterial chemoembolisation (tace) for hepatocellular carcinoma: a systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296639/ https://www.ncbi.nlm.nih.gov/pubmed/37370776 http://dx.doi.org/10.3390/cancers15123166 |
work_keys_str_mv | AT lawsonalexander outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT kamarajahsiveshk outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT parentealessandro outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT pufalkamil outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT sundareyanramanivas outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT pawliktimothym outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT mayukting outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT shahtahir outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT kharkhanissalil outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT dasaribobbyvm outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis |